{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023234","form_type":"8-K","ticker":"OKUR","cik":"0001637715","company_name":"OnKure Therapeutics, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.523792+00:00","generated_at":"2026-06-22T03:48:24.100728+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Reneo reports Q3 net loss $13.0M, >80% enrolled in pivotal STRIDE study","bullets":["Net loss of $13.0M ($0.53 per share) vs $12.7M ($0.52) in Q3 2021.","Cash, equivalents & short-term investments total $116M as of Sept 30, 2022.","Over 80% enrollment in pivotal STRIDE study for PMM with mtDNA defects; topline data expected Q4 2023.","Positive Phase 1b results in LC-FAOD patients; planning Phase 2 study.","FDA and EMA confirmed positive data from STRIDE/STRIDE AHEAD could support registration."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023234","json":"https://secwatch.observer/filing/0000950170-22-023234.json","markdown":"https://secwatch.observer/filing/0000950170-22-023234.md","text":"https://secwatch.observer/filing/0000950170-22-023234.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/0000950170-22-023234-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/rphm-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:48:24.100728+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ba596408839daf35120467082bf94e116e89e36d","claim":"OnKure Therapeutics, Inc. reported the three months ended September 30, 2022 results: net income $13.0 million, EPS $0.53 per share.","evidence_excerpt":"The Company reported a net loss of $13.0 million, or $0.53 per share, for the three months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1637715/000095017022023234/0000950170-22-023234-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Net income","value":"$13.0 million"},{"label":"EPS","value":"$0.53 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}